Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

This study found that the carbohydrate-based excipient β-cyclodextrin forms a stable inclusion complex with the active ingredient of Minoxicapil®, potentially enhancing its formulation for hair-loss treatment, and in vitro assays suggest improved proliferation of DPC cells, supporting its use in topical treatments.

This review outlines diagnostic and treatment approaches for hirsutism, highlighting spironolactone or cyproterone acetate with oral contraceptives as the most effective therapy, and reports no new empirical results.

This review discusses baricitinib's applications for various inflammatory disorders and highlights its promising efficacy alongside potential adverse effects, advocating for further research before it becomes a standard treatment.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

This study found that nanocapsules formulated as a dispersion and applied with massage may enhance follicular uptake of clobetasol propionate while minimizing its skin penetration, offering a potential improvement over conventional treatments for scalp diseases.

This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.

This review discusses treatments for polycystic ovary syndrome, including lifestyle changes, oral contraceptives, and various medications, and reports no new clinical findings; the authors highlight the potential of statins and inositol for managing symptoms.

This study found that a combination of cyproterone acetate and ethinyl estradiol over one year did not affect glucose tolerance but increased total cholesterol, HDL cholesterol, and triglycerides in patients with moderate hyperandrogenism.

In this case study, the authors identified a circulating low molecular weight inhibitor that may contribute to insulin resistance in a woman with acanthosis nigricans and polycystic ovary syndrome.

In this study, baricitinib showed effectiveness and good tolerability in treating severe alopecia areata over 52 weeks.

This compilation details various potential side effects and interactions of vitamin A, but it reports no new research findings.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This review discusses central centrifugal cicatricial alopecia in adult women of African descent and reports no clinical results; the authors highlight traditional treatments and their impact on quality of life.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

This study found that vismodegib promotes Basal cell carcinoma regression by inducing tumor differentiation but leaves a small population of quiescent cells that can drive relapse, which can be eliminated by adding a Wnt signaling inhibitor.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Results are not reported in this article by Zizhuo Li et al. on baricitinib as a treatment for lichen planopilaris.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This study found that treatment with leuprolide plus cyclic estrogen/progestin may lead to a faster and greater improvement in hirsutism compared to a standard oral contraceptive regimen.

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.

This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.